Literature DB >> 25715681

Endocannabinoid Catabolic Enzymes Play Differential Roles in Thermal Homeostasis in Response to Environmental or Immune Challenge.

Sara R Nass1, Jonathan Z Long, Joel E Schlosburg, Benjamin F Cravatt, Aron H Lichtman, Steven G Kinsey.   

Abstract

Cannabinoid receptor agonists, such as Δ(9)-THC, the primary active constituent of Cannabis sativa, have anti-pyrogenic effects in a variety of assays. Recently, attention has turned to the endogenous cannabinoid system and how endocannabinoids, including 2-arachidonoylglycerol (2-AG) and anandamide, regulate multiple homeostatic processes, including thermoregulation. Inhibiting endocannabinoid catabolic enzymes, monoacylglycerol lipase (MAGL) or fatty acid amide hydrolase (FAAH), elevates levels of 2-AG or anandamide in vivo, respectively. The purpose of this experiment was to test the hypothesis that endocannabinoid catabolic enzymes function to maintain thermal homeostasis in response to hypothermic challenge. In separate experiments, male C57BL/6J mice were administered a MAGL or FAAH inhibitor, and then challenged with the bacterial endotoxin lipopolysaccharide (LPS; 2 mg/kg ip) or a cold (4 °C) ambient environment. Systemic LPS administration caused a significant decrease in core body temperature after 6 h, and this hypothermia persisted for at least 12 h. Similarly, cold environment induced mild hypothermia that resolved within 30 min. JZL184 exacerbated hypothermia induced by either LPS or cold challenge, both of which effects were blocked by rimonabant, but not SR144528, indicating a CB1 cannabinoid receptor mechanism of action. In contrast, the FAAH inhibitor, PF-3845, had no effect on either LPS-induced or cold-induced hypothermia. These data indicate that unlike direct acting cannabinoid receptor agonists, which elicit profound hypothermic responses on their own, neither MAGL nor FAAH inhibitors affect normal body temperature. However, these endocannabinoid catabolic enzymes play distinct roles in thermoregulation following hypothermic challenges.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25715681      PMCID: PMC4477849          DOI: 10.1007/s11481-015-9593-1

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  37 in total

Review 1.  Actions of various marihuana derivatives in man.

Authors:  L E Hollister
Journal:  Pharmacol Rev       Date:  1971-12       Impact factor: 25.468

2.  Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects.

Authors:  Steven G Kinsey; Laura E Wise; Divya Ramesh; Rehab Abdullah; Dana E Selley; Benjamin F Cravatt; Aron H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2013-02-14       Impact factor: 4.030

3.  N-arachidonyl maleimide potentiates the pharmacological and biochemical effects of the endocannabinoid 2-arachidonylglycerol through inhibition of monoacylglycerol lipase.

Authors:  James J Burston; Laura J Sim-Selley; John P Harloe; Anu Mahadevan; Raj K Razdan; Dana E Selley; Jenny L Wiley
Journal:  J Pharmacol Exp Ther       Date:  2008-08-05       Impact factor: 4.030

4.  A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol.

Authors:  Jacqueline L Blankman; Gabriel M Simon; Benjamin F Cravatt
Journal:  Chem Biol       Date:  2007-12

5.  Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene.

Authors:  A Poltorak; X He; I Smirnova; M Y Liu; C Van Huffel; X Du; D Birdwell; E Alejos; M Silva; C Galanos; M Freudenberg; P Ricciardi-Castagnoli; B Layton; B Beutler
Journal:  Science       Date:  1998-12-11       Impact factor: 47.728

6.  Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain.

Authors:  S G Kinsey; J Z Long; S T O'Neal; R A Abdullah; J L Poklis; D L Boger; B F Cravatt; A H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2009-06-05       Impact factor: 4.030

7.  GABAA receptors modulate cannabinoid-evoked hypothermia.

Authors:  S M Rawls; R J Tallarida; D A Kon; E B Geller; Martin W Adler
Journal:  Pharmacol Biochem Behav       Date:  2004-05       Impact factor: 3.533

8.  Cannabinoid pharmacological properties common to other centrally acting drugs.

Authors:  Jenny L Wiley; Billy R Martin
Journal:  Eur J Pharmacol       Date:  2003-06-27       Impact factor: 4.432

9.  Physiology and pharmacology of hypothermia.

Authors:  K C Wong
Journal:  West J Med       Date:  1983-02

10.  Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects.

Authors:  Jonathan Z Long; Weiwei Li; Lamont Booker; James J Burston; Steven G Kinsey; Joel E Schlosburg; Franciso J Pavón; Antonia M Serrano; Dana E Selley; Loren H Parsons; Aron H Lichtman; Benjamin F Cravatt
Journal:  Nat Chem Biol       Date:  2008-11-23       Impact factor: 15.040

View more
  3 in total

1.  Discriminative Stimulus Properties of the Endocannabinoid Catabolic Enzyme Inhibitor SA-57 in Mice.

Authors:  Robert A Owens; Bogna Ignatowska-Jankowska; Mohammed Mustafa; Patrick M Beardsley; Jenny L Wiley; Abdulmajeed Jali; Dana E Selley; Micah J Niphakis; Benjamin F Cravatt; Aron H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2016-06-15       Impact factor: 4.030

2.  Rapid and profound rewiring of brain lipid signaling networks by acute diacylglycerol lipase inhibition.

Authors:  Daisuke Ogasawara; Hui Deng; Andreu Viader; Marc P Baggelaar; Arjen Breman; Hans den Dulk; Adrianus M C H van den Nieuwendijk; Adriann M C H van den Nieuwendijk; Marjolein Soethoudt; Tom van der Wel; Juan Zhou; Herman S Overkleeft; Manuel Sanchez-Alavez; Simone Mori; Simone Mo; William Nguyen; Bruno Conti; Xiaojie Liu; Yao Chen; Qing-Song Liu; Benjamin F Cravatt; Mario van der Stelt
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-14       Impact factor: 11.205

3.  Turning Over a New Leaf: Cannabinoid and Endocannabinoid Modulation of Immune Function.

Authors:  Guy A Cabral; Thomas J Rogers; Aron H Lichtman
Journal:  J Neuroimmune Pharmacol       Date:  2015-06-09       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.